RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/SHA-384/57DF7561CE28F32E3A3CC70A210AA3A25C0C29E6B50EF86AA705D4DCEBAB0AE6ECF248E94E8C914E65742BF322045CA0http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/57DF7561CE28F32E3A3CC70A210AA3A25C0C29E6B50EF86AA705D4DCEBAB0AE6ECF248E94E8C914E65742BF322045CA0http://www.w3.org/2000/01/rdf-schema#comment"Short-term treatment of nascent melanoma tumors with PAK inhibitors that block RhoJ signaling halts the growth of BRAF mutant melanoma tumors in vivo and induces apoptosis in melanoma cells in vitro via a BAD-dependent mechanism. As up to 50% of BRAF mutant human melanomas express high levels of RhoJ these studies nominate the RhoJ-BAD signaling network as a therapeutic vulnerability for fledgling BRAF mutant human tumor"xsd:string
http://purl.uniprot.org/uniprot/#_A293BDD25892E39BABBB85AA1D717B9B41F071E754FA1D7C97D402FB438582593874B1023C7C56AB69FD4CCA4F535E78http://www.w3.org/1999/02/22-rdf-syntax-ns#subjecthttp://purl.uniprot.org/SHA-384/57DF7561CE28F32E3A3CC70A210AA3A25C0C29E6B50EF86AA705D4DCEBAB0AE6ECF248E94E8C914E65742BF322045CA0
http://purl.uniprot.org/uniprot/Q7Z513http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/57DF7561CE28F32E3A3CC70A210AA3A25C0C29E6B50EF86AA705D4DCEBAB0AE6ECF248E94E8C914E65742BF322045CA0
http://purl.uniprot.org/uniprot/#_Q7Z513-mappedCitation-28753606http://purl.uniprot.org/core/mappedAnnotationhttp://purl.uniprot.org/SHA-384/57DF7561CE28F32E3A3CC70A210AA3A25C0C29E6B50EF86AA705D4DCEBAB0AE6ECF248E94E8C914E65742BF322045CA0